Lyra Therapeutics, Inc.

NasdaqGM:LYRA Stock Report

Mkt Cap: US$85.0m

We’ve recently updated our valuation analysis.

Lyra Therapeutics Valuation

Is LYRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LYRA?

Other financial metrics that can be useful for relative valuation.

LYRA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does LYRA's PB Ratio compare to its peers?

The above table shows the PB ratio for LYRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.8x
DARE Daré Bioscience
4.4x65.2%US$114.9m
LPCN Lipocine
1.3x10.6%US$47.3m
EYEN Eyenovia
3.7x59.4%US$76.2m
OCUP Ocuphire Pharma
6x55.4%US$71.0m
LYRA Lyra Therapeutics
0.9x9.0%US$85.0m

Price-To-Book vs Peers: LYRA is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (3.8x).


Price to Earnings Ratio vs Industry

How does LYRA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.5%
n/an/an/a

Price-To-Book vs Industry: LYRA is good value based on its Price-To-Book Ratio (0.9x) compared to the US Pharmaceuticals industry average (1.9x)


Price to Book Ratio vs Fair Ratio

What is LYRA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LYRA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LYRA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of LYRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LYRA ($2.67) is trading above our estimate of fair value ($1.88)

Significantly Below Fair Value: LYRA is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LYRA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.67
US$17.75
+564.8%
22.0%US$24.00US$14.00n/a4
Jan ’24US$3.14
US$17.75
+465.3%
22.0%US$24.00US$14.00n/a4
Dec ’23US$3.36
US$17.75
+428.3%
22.0%US$24.00US$14.00n/a4
Nov ’23US$4.69
US$17.75
+278.5%
22.0%US$24.00US$14.00n/a4
Oct ’23US$5.01
US$17.75
+254.3%
22.0%US$24.00US$14.00n/a4
Sep ’23US$5.88
US$17.75
+201.9%
22.0%US$24.00US$14.00n/a4
Aug ’23US$6.51
US$17.75
+172.7%
22.0%US$24.00US$14.00n/a4
Jul ’23US$5.39
US$19.25
+257.1%
24.7%US$24.00US$14.00n/a4
Jun ’23US$5.50
US$19.25
+250.0%
24.7%US$24.00US$14.00n/a4
May ’23US$5.65
US$23.50
+315.9%
27.0%US$29.00US$13.00n/a4
Apr ’23US$4.15
US$23.50
+466.3%
27.0%US$29.00US$13.00n/a4
Mar ’23US$5.01
US$24.00
+379.0%
26.6%US$29.00US$15.00n/a3
Feb ’23US$4.49
US$24.00
+434.5%
26.6%US$29.00US$15.00n/a3
Jan ’23US$4.36
US$27.00
+519.3%
8.0%US$29.00US$24.00US$3.143
Dec ’22US$5.34
US$26.25
+391.6%
8.7%US$29.00US$24.00US$3.364
Nov ’22US$7.27
US$26.50
+264.5%
7.8%US$29.00US$24.00US$4.694
Oct ’22US$9.41
US$26.75
+184.3%
8.9%US$30.00US$24.00US$5.014
Sep ’22US$8.01
US$26.75
+234.0%
8.9%US$30.00US$24.00US$5.884
Aug ’22US$6.44
US$27.00
+319.3%
8.3%US$30.00US$24.00US$6.514
Jul ’22US$7.88
US$27.00
+242.6%
8.3%US$30.00US$24.00US$5.394
Jun ’22US$7.63
US$26.75
+250.6%
7.2%US$29.00US$24.00US$5.504
May ’22US$10.07
US$30.25
+200.4%
24.8%US$43.00US$24.00US$5.654
Apr ’22US$11.42
US$30.25
+164.9%
24.8%US$43.00US$24.00US$4.154
Mar ’22US$15.61
US$29.75
+90.6%
22.3%US$41.00US$24.00US$5.014
Feb ’22US$10.89
US$26.00
+138.8%
6.3%US$28.00US$24.00US$4.493
Jan ’22US$11.40
US$26.00
+128.1%
6.3%US$28.00US$24.00US$4.363

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies